Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
US6114315A · kind A · utility
14Cited by
7References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 11, 1998 |
| Grant date | Sep 5, 2000 |
| Priority date | — |
| Expiry date | Jun 11, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/5377
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for the treatment or prevention of major depressive disorder with anxiety without concomitant therapy with other anti-depressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.